These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37168086)

  • 1. Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study.
    Lee J; Costa-Dookhan K; Panganiban K; MacKenzie N; Treen QC; Chintoh A; Remington G; Müller DJ; Sockalingam S; Gerretsen P; Sanches M; Karnovsky A; Stringer KA; Ellingrod VL; Tso IF; Taylor SF; Agarwal SM; Hahn MK; Ward KM
    Front Psychiatry; 2023; 14():1169787. PubMed ID: 37168086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures.
    Lee J; Xue X; Au E; McIntyre WB; Asgariroozbehani R; Panganiban K; Tseng GC; Papoulias M; Smith E; Monteiro J; Shah D; Maksyutynska K; Cavalier S; Radoncic E; Prasad F; Agarwal SM; Mccullumsmith R; Freyberg Z; Logan RW; Hahn MK
    Transl Psychiatry; 2024 Jan; 14(1):19. PubMed ID: 38199991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester, UK.
    Heald A; Daly C; Warner-Levy JJ; Williams R; Meehan C; Livingston M; Pillinger T; Hussain L; Firth J
    Ann Gen Psychiatry; 2024 Jan; 23(1):1. PubMed ID: 38172807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain.
    Zapata RC; Rosenthal SB; Fisch K; Dao K; Jain M; Osborn O
    Sci Rep; 2020 Oct; 10(1):18581. PubMed ID: 33122657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children.
    Libowitz MR; Nurmi EL
    Front Psychiatry; 2021; 12():623681. PubMed ID: 33776816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight and metabolic changes in early psychosis-association with daily quantification of medication exposure during the first hospitalization.
    Vochoskova K; McWhinney SR; Fialova M; Kolenic M; Spaniel F; Svancer P; Boron P; Okaji Y; Trancik P; Hajek T
    Acta Psychiatr Scand; 2023 Sep; 148(3):265-276. PubMed ID: 37528692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment.
    Khandker R; Chekani F; Limone B; Thiel E
    BMC Psychiatry; 2022 Feb; 22(1):133. PubMed ID: 35183142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
    Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
    J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.
    Tek C; Kucukgoncu S; Guloksuz S; Woods SW; Srihari VH; Annamalai A
    Early Interv Psychiatry; 2016 Jun; 10(3):193-202. PubMed ID: 25962699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis.
    Lamichhane S; Dickens AM; Sen P; Laurikainen H; Borgan F; Suvisaari J; Hyötyläinen T; Howes O; Hietala J; Orešič M
    Schizophr Bull; 2021 Jan; 47(1):160-169. PubMed ID: 32609372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort).
    Ter Hark SE; Jamain S; Schijven D; Lin BD; Bakker MK; Boland-Auge A; Deleuze JF; Troudet R; Malhotra AK; Gülöksüz S; Vinkers CH; Ebdrup BH; Kahn RS; Leboyer M; Luykx JJ
    J Psychopharmacol; 2020 May; 34(5):524-531. PubMed ID: 32126890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic Connections between Schizophrenia, Antipsychotic Drugs and Metabolic Syndrome: A Variety of Players.
    Molina JD; Avila S; Rubio G; López-Muñoz F
    Curr Pharm Des; 2021; 27(39):4049-4061. PubMed ID: 34348619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis.
    Medrano S; Abdel-Baki A; Stip E; Potvin S
    Psychopharmacol Bull; 2018 Jun; 48(4):25-61. PubMed ID: 30618474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sertindole for schizophrenia.
    Lewis R; Bagnall AM; Leitner M
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001715. PubMed ID: 16034864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.